Breast Cancer (Therapy)

FDA Okays Prophylactic Use of Tamoxifen

Published in Women's Health Weekly, November 16th, 1998

The U.S. Food and Drug Administration on November 5, 1998, approved the use of the breast cancer drug tamoxifen to prevent the disease in healthy women.

This clears the popular breast cancer drug, sold by British pharmaceuticals and chemicals giant Zeneca Group Plc under the name Nolvadex, for use in preventing breast cancer in women considered at high risk.

"Breast cancer is the second leading cause of cancer death in American women and accounts for 31 percent of all cancers among women. [This] action provides an important new option for some women at heightened risk of breast cancer," U.S. Department of Health and Human Services Secretary Donna...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-11-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry